Gabapentin vs Lyrica

Two closely related medications for nerve pain and seizures — structurally similar with the same target, but with important pharmacokinetic and regulatory differences.

Overview

Gabapentin and pregabalin (Lyrica) belong to the gabapentinoid drug class — a group of medications structurally related to GABA (gamma-aminobutyric acid) but which do not actually activate GABA receptors. Despite their name, they work through a completely different mechanism: binding to voltage-gated calcium channels in the nervous system. Both are used to treat neuropathic (nerve) pain and seizure disorders, and both are among the most frequently prescribed medications in the United States.

Pregabalin was developed after gabapentin and was designed to address some of gabapentin's pharmacokinetic limitations — particularly its variable, nonlinear absorption. Understanding these differences helps explain why one might be preferred over the other in a given clinical scenario.

How Each Works

Both gabapentin and pregabalin bind to the alpha-2-delta (α2δ) subunit of voltage-gated calcium channels in the central and peripheral nervous system. These channels normally regulate the influx of calcium into nerve terminals, which in turn triggers the release of excitatory neurotransmitters like glutamate, substance P, and norepinephrine. In conditions involving neuropathic pain — such as diabetic neuropathy or postherpetic neuralgia — these channels become hyperactive, contributing to the abnormal pain signaling characteristic of these conditions.

By binding to the α2δ subunit, gabapentinoids reduce calcium channel activity and thereby decrease the excessive release of excitatory neurotransmitters. This "quieting" of overactive pain-transmitting neurons underlies their analgesic effect in neuropathic conditions. The same mechanism also contributes to their anticonvulsant properties in partial-onset seizures.

The Absorption Difference

The most pharmacologically significant difference between the two drugs is how the body absorbs them. Gabapentin is absorbed from the gastrointestinal tract via a saturable, carrier-mediated transport system. This means that as the amount increases, the proportion that is actually absorbed decreases — absorption is nonlinear. At lower amounts, a relatively high percentage is absorbed; at higher amounts, absorption becomes less efficient and more variable. This makes gabapentin's pharmacokinetics somewhat unpredictable at higher doses and requires the daily amount to be divided into multiple administrations to maintain more stable blood levels.

Pregabalin uses a similar but higher-capacity transport mechanism, resulting in linear, predictable absorption across its therapeutic range — approximately 90% of an oral dose is absorbed regardless of the amount. This more reliable pharmacokinetic profile means blood levels are more consistent and predictable, which can translate to more reliable therapeutic effect. It also allows pregabalin to be effective with twice-daily dosing in most cases.

Approved Indications

Both drugs share approvals for neuropathic pain (specifically postherpetic neuralgia and diabetic peripheral neuropathy) and as adjunctive therapy for partial-onset seizures. Pregabalin additionally holds FDA approvals for fibromyalgia and neuropathic pain associated with spinal cord injury — areas where gabapentin has evidence but not formal approval. Gabapentin's extended-release formulation (Horizant) is approved specifically for restless legs syndrome.

Controlled Substance Status

Pregabalin (Lyrica) is classified as a Schedule V controlled substance by the DEA, reflecting its recognized (though relatively lower) potential for misuse compared to higher schedules. Gabapentin is not federally scheduled but has been added to Schedule V by several states (including Michigan, Tennessee, Kentucky, and others) due to growing evidence of misuse, diversion, and increasing rates of gabapentin-related emergency department visits. This regulatory landscape continues to evolve.

Side Effects

Both medications share a common side effect profile: dizziness and sedation are the most frequently reported effects, particularly when starting treatment or during dose increases. Peripheral edema (swelling in the legs and feet), weight gain, and fatigue are also common with both. These effects are generally more pronounced with higher amounts and in older patients. Both can impair driving and cognitive performance, particularly when first starting treatment.

Both carry FDA warnings regarding respiratory depression, particularly when combined with CNS depressants such as opioids, benzodiazepines, or alcohol. This combination has been implicated in fatal overdoses and requires careful clinical monitoring.

Which Is Right for You?

Gabapentin is often tried first for neuropathic pain due to its lower cost (generic) and the large body of clinical experience with it. Pregabalin may be preferred when more predictable drug levels are desired, when fibromyalgia or spinal cord injury pain is the indication, or when a patient has not responded adequately to gabapentin. Cost is a practical factor — branded Lyrica is expensive, though generic pregabalin is now widely available. Your doctor is the right person to determine which medication, and at what dosing schedule, is appropriate for your condition.

Frequently Asked Questions